Serum total bilirubin and long-term prognosis of patients with new-onset non-ST elevation myocardial infarction: a cohort study

[1]  Yi Huang,et al.  Physiologically increased total bilirubin is associated with reduced risk of first myocardial infarction: A meta-analysis and dose-response analysis. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[2]  J. Kaski,et al.  Total coronary occlusion in non ST elevation myocardial infarction: Time to change our practice? , 2021, International journal of cardiology.

[3]  Hongbing Yan,et al.  Prognostic Value of Total Bilirubin in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Coronary Intervention , 2020, Frontiers in Cardiovascular Medicine.

[4]  Yanan Xu,et al.  Predictive efficacy of neutrophil-to-lymphocyte ratio for long-term prognosis in new onset acute coronary syndrome: a retrospective cohort study , 2020, BMC Cardiovascular Disorders.

[5]  S. Doğan,et al.  The predictive value of age, creatinine, ejection fraction score for in-hospital mortality in patients with cardiogenic shock. , 2019, Coronary artery disease.

[6]  H. Drummond,et al.  Targeting Heme Oxygenase-1 in Cardiovascular and Kidney Disease , 2019, Antioxidants.

[7]  Fen Liu,et al.  Mean platelet volume and coronary plaque vulnerability: an optical coherence tomography study in patients with non-ST-elevation acute coronary syndrome , 2019, BMC Cardiovascular Disorders.

[8]  Juan Zhou,et al.  Relation of Direct, Indirect, and Total bilirubin to Adverse Long-term Outcomes Among Patients With Acute Coronary Syndrome. , 2019, The American journal of cardiology.

[9]  Fen Liu,et al.  New Insights into the Association between Fibrinogen and Coronary Atherosclerotic Plaque Vulnerability: An Intravascular Optical Coherence Tomography Study , 2019, Cardiovascular therapeutics.

[10]  A. Bulmer,et al.  Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. , 2018, American journal of physiology. Heart and circulatory physiology.

[11]  G. Çinier,et al.  Clinical characteristics and outcomes of acute coronary syndrome patients with intra-aortic balloon pump inserted in intensive cardiac care unit of a tertiary clinic. , 2018, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[12]  Lyanne M. Kieneker,et al.  Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End‐Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach , 2017, Journal of the American Heart Association.

[13]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[14]  E. Yıldırım,et al.  The Role of Serum Bilirubin Levels in Predicting Troponin Positivity in Non-ST-Segment Elevation Acute Coronary Syndrome , 2017, Angiology.

[15]  Yong Peng,et al.  The correlation between serum total bilirubin and outcomes in patients with different subtypes of coronary artery disease. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[16]  A. Goldfine,et al.  Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. , 2017, The Journal of clinical investigation.

[17]  R. Chowdhury,et al.  Circulating Total Bilirubin and Risk of Incident Cardiovascular Disease in the General Population , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[18]  S. Aydoǧdu,et al.  The Prognostic Role of Serum Total Bilirubin in Non-ST Segment Elevation Myocardial Infarction , 2014, Angiology.

[19]  O. Uysal,et al.  Relation Between Serum Total Bilirubin Levels and Severity of Coronary Artery Disease in Patients With Non-ST-Segment Elevation Myocardial Infarction , 2014, Angiology.

[20]  O. Orscelik,et al.  Bilirubin Levels and the Burden of Coronary Atherosclerosis in Patients With STEMI , 2013, Angiology.

[21]  M. Bozbay,et al.  Prognostic value of total bilirubin in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. , 2013, The American journal of cardiology.

[22]  J. Kastelein,et al.  Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? , 2011, Journal of Lipid Research.

[23]  Kari Kuulasmaa,et al.  World Health Organization definition of myocardial infarction: 2008-09 revision. , 2011, International journal of epidemiology.

[24]  Y. Kihara,et al.  Change in Bilirubin Level Following Acute Myocardial Infarction Is an Index for Heme Oxygenase Activation , 2010, Southern medical journal.

[25]  M. Pfeffer,et al.  Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program , 2009, European journal of heart failure.

[26]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[27]  R. Wennberg,et al.  Interactions of bilirubin with isolated presynaptic nerve terminals: Functional effects on the uptake and release of neurotransmitters , 1993, Cellular and Molecular Neurobiology.

[28]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[29]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[30]  I. Tikkanen,et al.  Expression of heme oxygenase-1 in response to myocardial infarction in rats. , 2002, Journal of molecular and cellular cardiology.

[31]  延吉 正清.  Coronary Intervention-欧米との比較- , 1995 .

[32]  S. Ebrahim,et al.  Serum bilirubin and risk of ischemic heart disease in middle-aged British men. , 1995, Clinical chemistry.